Search Results - Leonardo Salese

  • Showing 1 - 16 results of 16
Refine Results
  1. 1
    The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

    The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe by Alessandro Armuzzi, M. Tarallo, James Lucas, Daniel Bluff, Benjamin Hoskin, Danielle Bargo, Joseph C. Cappelleri, Leonardo Salese, Marco DiBonaventura

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Review of the epidemiology and burden of ulcerative colitis in Latin America

    Review of the epidemiology and burden of ulcerative colitis in Latin America by Paulo Gustavo Kotze, Flávio Steinwurz, Carlos Fernando de Magalhães Francisconi, Cyrla Zaltman, Pinheiro Marcia, Leonardo Salese, Darío Ponce de León

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    S962 Presence of Risk Factors Associated With Colectomy Among Patients With Colectomy in the Tofacitinib OCTAVE Ulcerative Colitis Clinical Program

    S962 Presence of Risk Factors Associated With Colectomy Among Patients With Colectomy in the Tofacitinib OCTAVE Ulcerative Colitis Clinical Program by David T. Rubin, Leonardo Salese, Paulo Gustavo Kotze, John Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    P366 CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysis of OCTAVE Induction 1 and 2

    P366 CRP levels and PMS as early predictors of clinical and endoscopic outcomes in adult patients with moderately-to-severely active UC treated with tofacitinib: a post hoc analysi... by Marla C. Dubinsky, David Hudesman, Flávio Steinwurz, Nicole Kulisek, Leonardo Salese, Jerome Paulissen, Chinyu Su, Darío Ponce de León, Fernando Magro

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme

    P539 Assessment of age as a risk factor for adverse events in patients from the tofacitinib ulcerative colitis clinical programme by Gary R. Lichtenstein, Brian Bressler, Séverine Vermeire, Carlos Fernando de Magalhães Francisconi, Nervin Lawendy, Harry Shi, Leonardo Salese, Donna T. Judd, Edward V. Loftus

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

    Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status by William J. Sandborn, Laurent Peyrin–Biroulet, Ala I. Sharara, Chinyu Su, Irene Modesto, Rajiv Mundayat, Levent Mert Günay, Leonardo Salese, Bruce E. Sands

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Presence of risk factors associated with colectomy among patients with ulcerative colitis: a <i>post hoc</i> analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program

    Presence of risk factors associated with colectomy among patients with ulcerative colitis: a <i>post hoc</i> analysis of data from the tofacitinib OCTAVE ulcerative colitis clinica... by David T. Rubin, Leonardo Salese, Mitchell J. Cohen, Paulo Gustavo Kotze, John Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

    Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe by Alessandro Armuzzi, Marco daCosta DiBonaventura, M. Tarallo, James Lucas, Daniel Bluff, Benjamin Hoskin, Danielle Bargo, Joseph C. Cappelleri, Daniel Quirk, Leonardo Salese

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open

    P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open by Jessica R. Allegretti, K Gecse, Michael Chiorean, Marjorie Argollo, Ximing Guo, Nervin Lawendy, Chunyan Su, Rajiv Mundayat, Jerome Paulissen, Leonardo Salese, Peter M. Irving

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain

    Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Susta... by Jessica R. Allegretti, K Gecse, Michael Chiorean, Marjorie Argollo, Xiang Guo, Nervin Lawendy, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Leonardo Salese, Peter M. Irving

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

    Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme by Kevin Winthrop, Edward V. Loftus, Daniel C. Baumgart, Walter Reinisch, Chudy I. Nduaka, Nervin Lawendy, Gary Chan, Rajiv Mundayat, Gary S. Friedman, Leonardo Salese, Andrew Thorpe, Chinyu Su

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme

    P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical progr... by B E Sands, Pam R. Taub, B G Feagan, Alessandro Armuzzi, Adérson Omar Mourão Cintra Damião, Nervin Lawendy, Gastón Solano, Kenneth Kwok, John Woolcott, Leonardo Salese, Chunyan Su

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis

    Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis by Bruce E. Sands, Pam R. Taub, Alessandro Armuzzi, Gary S. Friedman, Michele Moscariello, Nervin Lawendy, Ronald Pedersen, Gary Chan, Chudy I. Nduaka, Daniel Quirk, Leonardo Salese, Chinyu Su, Brian G. Feagan

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

    Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program by Gary R. Lichtenstein, Brian Bressler, Carlos Fernando de Magalhães Francisconi, Séverine Vermeire, Nervin Lawendy, Leonardo Salese, Gosford Sawyerr, Hongjiong Shi, Chinyu Su, Donna T. Judd, Thomas V. Jones, Edward V. Loftus

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study

    DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, lo... by Bruce E. Sands, Alan C. Moss, Alessandro Armuzzi, John K. Marshall, James O. Lindsay, William J. Sandborn, Silvio Danese, Marco Zerôncio, Irene Modesto, Leonardo Salese, Nervin Lawendy, H Zhang, Chunyan Su

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open

    Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open by Bruce E. Sands, Alessandro Armuzzi, John K. Marshall, James O. Lindsay, William J. Sandborn, Silvio Danese, Julián Panés, Brian Bressler, Jean‐Frédéric Colombel, Nervin Lawendy, Eric S. Maller, Haiying Zhang, Gary Chan, Leonardo Salese, Konstantinos Tsilkos, Amy Marren, Chinyu Su

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: